Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EPS (Basic): 2012-2025

Historic EPS (Basic) for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$0.88.

  • Enanta Pharmaceuticals' EPS (Basic) rose 35.29% to -$0.88 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.84, marking a year-over-year increase of 29.93%. This contributed to the annual value of -$3.84 for FY2025, which is 29.93% up from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' EPS (Basic) stood at -$0.88, which was down 3.53% from -$0.85 recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year EPS (Basic) high stood at -$0.85 for Q2 2025, and its period low was -$1.86 during Q2 2023.
  • In the last 3 years, Enanta Pharmaceuticals' EPS (Basic) had a median value of -$1.33 in 2023 and averaged -$1.30.
  • In the last 5 years, Enanta Pharmaceuticals' EPS (Basic) plummeted by 263.33% in 2021 and then spiked by 42.47% in 2024.
  • Enanta Pharmaceuticals' EPS (Basic) (Quarterly) stood at -$1.48 in 2021, then grew by 6.08% to -$1.39 in 2022, then declined by 13.67% to -$1.58 in 2023, then soared by 33.54% to -$1.05 in 2024, then spiked by 35.29% to -$0.88 in 2025.
  • Its EPS (Basic) was -$0.88 in Q3 2025, compared to -$0.85 in Q2 2025 and -$1.06 in Q1 2025.